Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Clinical Trials Search

As a clinical trial candidate at Methodist, you’re offered unique access to new drugs and technology being studied to improve patient outcomes.
Filter by Disease or Condition
Showing 71-79 results of 79
Lung Cancer

S2302

Official Title: Non-chemotherapy treatment (Ramucirumab plus Pembrolizumab) or usual care for advanced non-small cell lung cancer following immunotherapy
Study Purpose: To compare overall survival in participants previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer randomized to Pembrolizumab and Ramucirumab versus standard of care. 
Status: Recruiting
Heart and Vascular

SOLVE-CRT

Official Title: Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)
Study Purpose: This study is a prospective, multi-center, randomized, controlled, double blinded, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy.
Status: Active, Not Recruiting
Breast Cancer

SWOG S1706

Official Title: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer
Study Purpose: To determine if adding the drug olaparib to the usual radiation therapy for inflammatory breast cancer will decrease the risk of cancer returning.
Status: Recruiting
Urinary Cancer

SWOG S1802

Official Title: Comparing the Treatment Outcome of Standard Systemic Therapy Only versus Standard Systemic Therapy in Combination with Either Surgery or Radiation Therapy, for Patients with Advanced Prostate Cancer
Study Purpose: To compare the effects, good and/or bad, of adding prostate removal surgery or radiation therapy to standard therapy which is used to treat prostate cancer.
Status: Recruiting
Blood Cancer

SWOG S1803

Official Title: Phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (dramatic study)
Study Purpose: The purpose of this part of the study (screening consent) is to allow the study doctor to follow the progress through transplant and see if the treatment portion is appropriate.   
Status: Recruiting
Urinary Cancer

SWOG S1931

Official Title: Comparing The Outcome Of Immunotherapy-Based Drug Combination Therapy With Or Without Surgery To Remove The Kidney In Metastatic Kidney Cancer
Study Purpose: To compare Standard Systemic Therapy alone to Standard Systemic Therapy plus surgery to remove all or part of the kidney with tumor.
Status: Recruiting
Gastrointestinal Cancer

SWOG S2001

Official Title: A testing the addition of pembrolizumab, an immunotherapy cancer drug to olaparib alone as therapy for patients with pancreatic cancer that has spread with unhealthy tumor suppressor genes.
Study Purpose: To compare the usual treatment alone to using pembrolizumab plus the usual treatment.
Status: Recruiting
Lung Cancer

XmAb717-06

Official Title: Aphase 1b/2 Open Label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab In Combination With Chemotherapy as First Line Treatment In Patients with Advanced Non-Small Lung Cancer 
Study Purpose: To find a safe, tolerable, and recommended dose of vudalimab for people with locally advanced (unresectable) or metastatic NSCL when combine with chemotherapy.
Status: Recruiting
Gynecologic Cancer

ZN-c3-005 - Zentalis

Official Title: A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN‑c3 (Azenosertib) in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 
Study Purpose: To evaluate the safety, clinical activity, and pharmacokinetics of ZN-c3 (also known as azenosertib) in subjects with platinum-resistant, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer 
Status: Recruiting